Press Releases

Company News
Summary ToggleAcura Pharmaceuticals Licenses LIMITx™ LTX-03
Jul 02, 2019
Agreement Provides For Completion of Development and Commercialization Transaction Valued at up to $21.3 Million , not including Royalties PALATINE, Ill. , July 02, 2019 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC Pink: ACUR) today announced a License, Development and Commercialization

Read more

Summary ToggleAcura Pharmaceuticals Announces Third Quarter 2018 Financial Results
Nov 27, 2018
PALATINE, Ill. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and nine months ended September 30, 2018 .

Read more

Summary ToggleAcura Pharmaceuticals, Inc. Restructures Debt Obligations
Oct 09, 2018
PALATINE, Ill. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) , a specialty pharmaceutical company focused on innovating abuse deterrent drugs , today announced that on October 5, 2018 we restructured our debt obligations by (a) receiving an additional $1.8 million

Read more

Summary ToggleAcura Pharmaceuticals Announces Second Quarter 2018 Financial Results
Aug 14, 2018

PALATINE, Ill. , Aug. 14, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and six months ended June 30, 2018 . The Company reported a net loss of $2.8 million or

Read more

Summary ToggleAcura Pharmaceuticals Announces First Quarter 2018 Financial Results
Jun 29, 2018

PALATINE, Ill. , June 29, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC PINK:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three months ended March 31, 2018 . The Company reported for the first quarter 2018 a net

Read more

Summary ToggleAcura Pharmaceuticals Announces Fourth Quarter 2017 and Full Year 2017 Financial Results
Jun 07, 2018

PALATINE, Ill. , June 07, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC PINK:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and twelve months ended December 31, 2017 .

Read more

Summary ToggleAcura Pharmaceuticals Announces Successful Results from Study AP-LTX-301
Jan 08, 2018
*** LIMITx™ Product LTX-03 Advancing to IND ***

Read more

Summary ToggleAcura Pharmaceuticals Announces Third Quarter 2017 Financial Results
Nov 13, 2017
PALATINE, Ill. , Nov. 13, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and nine months ended September 30, 2017 .

Read more

Summary ToggleAcura Pharmaceuticals Advances LTX-03 and its LIMITx™ Technology
Oct 09, 2017
PALATINE, Ill. , Oct. 09, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that topline results from clinical study AP-LTX-300 (Study 300) for its LIMITx™ oral abuse deterrent drug LTX-03

Read more

Summary ToggleAcura Pharmaceuticals Presenting New LIMITx™ Clinical Data at the 19th Annual Rodman & Renshaw Conference
Sep 11, 2017
PALATINE, Ill. , Sept. 11, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced the results from the previously undisclosed exploratory arm of its second LIMITx™ clinical study, study

Read more

Summary ToggleAcura Pharmaceuticals to Present at the 19th Annual RODMAN & RENSHAW Conference
Aug 31, 2017
PALATINE, Ill. , Aug. 31, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that Bob Jones , President and Chief Executive Officer, will present at the 19 th Annual Rodman & Renshaw Global

Read more

Summary ToggleAcura Pharmaceuticals Announces Second Quarter 2017 Financial Results
Aug 14, 2017
PALATINE, Ill. , Aug. 14, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and six months ended June 30, 2017 . The Company reported a net loss of $2.15 million or

Read more

Summary ToggleAcura Pharmaceuticals to Host Second Quarter 2017 Financial Results Conference Call on August 15, 2017
Aug 03, 2017
PALATINE, Ill. , Aug. 03, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for the second quarter 2017 following the close of financial markets

Read more

Summary ToggleAcura Pharmaceuticals Raises $4.0 Million in a Private Placement
Jul 24, 2017

*** Provides Funding to Advance Development of Products Utilizing LIMITx™ Technology ***

Read more

Summary ToggleAcura Pharmaceuticals Advances LTX-04 and its LIMITx™ Technology
Jun 28, 2017

*** Peak blood levels of abused LIMITx doses can be reduced up to 65% ***

Read more

Summary ToggleAcura Pharmaceutical Initiates Second Clinical Study on LTX-04
May 18, 2017
PALATINE, Ill. , May 18, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company has completed enrollment and initiated dosing in a second Phase 1 human pharmacokinetic trial of

Read more

Summary ToggleAcura Pharmaceuticals Announces First Quarter 2017 Financial Results
May 12, 2017
PALATINE, Ill. , May 12, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the first quarter ended March 31, 2017 . The Company reported net income of $0.4 million for the

Read more

Summary ToggleAcura Pharmaceuticals Announces Fourth Quarter 2016 and Full Year 2016 Financial Results
Mar 31, 2017
PALATINE, Ill. , March 31, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the year and three months ended December 31, 2016 .

Read more

Displaying 19 - 36 of 157 results